In these studies we compared the therapeutic efficacy and toxicity of 177Lu- and 90Y-anti-CD45 RIT as primary treatment in an immunocompetent, syngeneic murine myeloid leukemia model, and showed that 90Y was more effective than 177Lu for anti-CD45 RIT of AML. Here, PTPRC is linked to acute myeloid leukemia.